申请人:Schering Aktiengesellschaft
公开号:US06344454B1
公开(公告)日:2002-02-05
This invention describes the new, nonsteroidal gestagens of general formula I
in which
A, B, Ar, R1, R2 and R3 have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gestagen receptor. They can be used alone or in combination with estrogens in contraceptive preparations. In addition, they can be used for treating endometriosis. Together with estrogens, they can also be used in preparations for treating gynecological disorders, for treating premenstrual symptoms and for substitution therapy. Based on the androgenic action, they can also be used for male birth control, male HRT and hormone therapy and for treating andrological disease agents.
本发明描述了具有一般公式 I 的新非甾体孕激素:其中 A、B、Ar、R1、R2 和 R3 的含义在描述中更详细地指出。这些新化合物对孕激素受体的亲和力非常强。它们可以单独使用,也可以与雌激素结合用于避孕制剂中。此外,它们还可以用于治疗子宫内膜异位症。与雌激素结合时,它们还可用于治疗妇科疾病、治疗经前症状和替代疗法。基于其雄激素作用,它们还可用于男性避孕、男性激素替代疗法和激素治疗,以及治疗男科疾病。